The FDA is seeking advice this week from two of its advisory committees on how manufacturers of a major group of asthma drugs should study their potential risks.
asthma drugsFDA Panels to Advise on LABA Study DesignsMedPage Today Allergy & Immunology Tue, 03/09/2010 - 15:39
Beta-2 Receptor Variants Don't Affect LABA Response in Asthma (C...MedPage Today Allergy & Immunology Fri, 11/20/2009 - 10:17
Against expectations, asthma patients with different genotypes for the beta-2 adrenergic receptor all responded well to long-acting beta agonist (LABA) asthma drugs, researchers said. Asthma drug limits urgedSeattle Post-Intelligencer: Health and Fitness Thu, 12/11/2008 - 20:24
WASHINGTON -- Government health advisers recommended restrictions Thursday on some long-acting asthma drugs, although not Advair, a top-selling medication. Popular asthma drugs bring severe warningSeattle Post-Intelligencer: Health and Fitness Sat, 12/06/2008 - 01:26
WASHINGTON -- Two federal drug officials have concluded that asthma sufferers risk death if they continue to use four hugely popular asthma drugs -- Advair, Symbicort, Serevent and Foradil. FDA: Risks of new asthma drugs varyHeadlines from the Associated Press Fri, 12/05/2008 - 08:29
WASHINGTON (AP) -- The Food and Drug Administration says Advair, a widely used asthma drug, does not appear to have an increased risk of serious complications seen with some newer medicines.... |
